# A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

> **NCT05736965** · PHASE2 · RECRUITING · sponsor: **Shanghai Tong Ren Hospital** · enrollment: 58 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05736965
- **Lead sponsor:** Shanghai Tong Ren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-20
- **Primary completion:** 2025-03-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736965, "A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05736965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*